Skip to main content

Judge Rejects JnJ's $10B Talc Lawsuit Settlement

Judge Rejects JnJ's $10B Talc Lawsuit Settlement

Judge Rejects JnJ's $10B Talc Lawsuit Settlement

Introduction

Johnson & Johnson's shares fell more than 5% after a U.S. bankruptcy judge rejected its $10 billion settlement proposal aimed at resolving over 60,000 lawsuits. 

These lawsuits allege that the company’s talc-based baby powder and other products caused ovarian cancer due to asbestos contamination. This marks the third time J&J’s strategy to resolve the litigation through bankruptcy has failed in court.

Legal Setback and Future Plans

The proposed settlement would have ended current and future talc-related claims. However, following the court’s rejection, J&J announced it will now return to the tort system to defend itself against what it describes as “meritless” claims. The company also made it clear that it does not plan to appeal the ruling and told investors that plaintiffs are “sorely mistaken” if they believe a similar deal can be reached outside of bankruptcy.

Criticism and Financial Response

Opponents of the bankruptcy strategy — including lawyers for cancer victims and a government bankruptcy watchdog — argue that J&J is not facing financial hardship and should not use bankruptcy protections to manage litigation. In response to the court’s decision, J&J’s Chief Financial Officer stated the company is reversing $7 billion previously reserved for the bankruptcy settlement, calling it their “best and final offer.”

Product Safety and Market Performance

J&J continues to maintain that its talc products are safe, asbestos-free, and not linked to cancer. The company discontinued sales of talc-based baby powder in the U.S. in 2020, replacing it with a cornstarch-based formula. Following the court ruling, J&J’s stock dropped 5.4% to $156.82. Despite this, the stock has gained 14.7% year-to-date, with a market capitalization around $400 billion. The company reaffirmed its confidence in its 2025 financial targets and long-term outlook.

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Study Finds Toxic Metals in E-Cigs and U-Cigs Vapors

Categories: E-Cigarette: JUUL

As health concerns about e-cigarette use escalate, emerging research suggests that a newer class of vaping products—ultrasonic cigarettes or u-cigarettes—may pose even greater risks.

A study published in Environmental Health Perspectives in…

Appeals Court Upholds $611M Roundup Verdict

Categories: Roundup

A Missouri appeals court has upheld a massive Roundup verdict originally totaling $1.5 billion, but significantly reduced the final amount Bayer and its Monsanto unit must pay to $611 million.

The case involved three plaintiffs from New…

Valsartan “Wave 2” Bellwether Trial Schedule Set by Court

Categories: Valsartan

As the first Valsartan bellwether trial approaches in September 2025, the federal judge overseeing the multidistrict litigation (MDL) is preparing a second set of trials.

This move comes in anticipation of the possibility that parties may…

✍️ FREE—3000 Pages Medical Record Review Trial!                
No Contract. No Risk—Fully Customized, Free!

Only 10 Firms Accepted—Offer Ends June 30!